Bayer's Pivotal Fortnight: Leadership, Litigation, and a 95% Rally on the Line

Bayer stock faces a pivotal fortnight with a Supreme Court hearing on glyphosate lawsuits and a new U.S. pharma chief. Analysts see upside if legal risks ease.

Bayer shares, having soared nearly 100% over the past year, now face a critical two-week period that will test both its operational momentum and its capacity to resolve a legacy of legal uncertainty. The stock's remarkable climb from an April 2025 low of 20.80 euros to a recent level around 41 euros has been fueled by pharmaceutical strength, but investors are now bracing for events that could redefine the company's fundamental outlook.

The immediate focus shifts to Washington D.C., where the U.S. Supreme Court is scheduled to hear arguments on April 27. The case, Durnell, centers on Bayer's "federal preemption" defense, which argues that federal approval from the EPA overrides state-level warning requirements for products like glyphosate. A favorable ruling for the Leverkusen-based conglomerate could render a significant portion of the thousands of pending lawsuits moot. This legal maneuver runs parallel to a proposed $7.25 billion settlement aimed at resolving existing and future claims linking glyphosate to non-Hodgkin lymphoma, with claimants having until June 4 to opt out.

This high-stakes legal calendar coincides with a major leadership appointment designed to bolster growth in Bayer's most crucial market. Effective May 1, 2026, Nelson Ambrogio will take the helm of the U.S. pharmaceuticals business. His mandate is to accelerate the division's dynamism, which currently serves as the group's central profit engine. Key growth drivers are the kidney and heart drug Kerendia and the cancer treatment Nubeqa, which analysts believe can offset patent expirations for older blockbusters like Xarelto and Eylea. Kerendia's potential was recently expanded with an EU approval for chronic heart failure in late March.

Financial health remains a work in progress. Management reported an 8.5% reduction in net financial debt to 29.8 billion euros at the end of the last fiscal year. However, the fundamental picture is still constrained by high provisions for U.S. legal risks. The company continues to anticipate a negative free cash flow for 2026 due to ongoing litigation payments, a point of concern for investors despite progress in streamlining corporate structures under CEO Bill Anderson.

Analyst opinions reflect this blend of operational promise and legal overhang. UBS recently reaffirmed its buy rating with a price target of 52 euros, implying roughly 27% upside from recent levels around 41.39 euros. Analyst Matthew Weston pins his optimism on the pharmaceutical pipeline. DZ Bank holds a more cautious view, upgrading its stance from "sell" to "hold" with a fair value estimate of 44 euros.

The coming days present a packed schedule for shareholders. The virtual Annual General Meeting on April 24 will include a vote on a dividend proposal of 0.11 euros per share, a largely symbolic payout that underscores the investment thesis is not about income but about legal and operational resolution. The ex-dividend date is set for April 27, the same day as the Supreme Court hearing. Furthermore, the company enters a quiet period for communications starting April 20 ahead of its first-quarter earnings release on May 12, making legal developments the primary short-term driver for the stock.

With the share price trading nearly 20% above its closely watched 200-day moving average near 34 euros, the stage is set for a volatile period. The twin catalysts of a potential legal breakthrough and sustained pharmaceutical execution will determine whether the stock's dramatic year-long recovery can be sustained.